Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

NCT07013851 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

MMRd/MSI-H Stage II-III Endometrial Cancer

Interventions

DRUG: Dostarlimab

Sponsor

Grupo Español de Investigación en Cáncer de Ovario

Collaborators

[object Object]